Editor: Farhadul Islam

Current Cancer Biomarkers

eBook: US $79 Special Offer (PDF + Printed Copy): US $136
Printed Copy: US $96
Library License: US $316
ISBN: 978-981-5079-37-1 (Print)
ISBN: 978-981-5079-36-4 (Online)
Year of Publication: 2023
DOI: 10.2174/97898150793641230101


Current Cancer Biomarkers is a comprehensive review on the status of biological markers for various types of cancer. It aims to update readers on current developments on the subject. The contents are divided into 5 sections covering a wide range of biomarkers and their diagnostic applications. The range of tumour biomarkers referenced here gives insights into molecular mechanisms behind cancer, including initiation, development, progression, prognosis, response to the therapeutic modalities, recurrence, and point-of-care application to detect cancer.

Key features :

-Introduction of the basic features of cancer markers

-Comprehensive and updated coverage of potential and effective biomarkers including genomic, epigenomic, transcriptomic, proteomic, cellular and morphologic factors

-Information on biomarkers in many types of cancers including breast cancer, colorectal cancer, skin cancer, leukemia, liver cancer and prostate cancer

-Applications of biomarkers in cancer diagnosis

-Structured contents with easy-to-understand sections and headings

-References for advanced readers

The updated information about different aspects of cancer markers in the experimental and clinical setting will enrich the reader's understanding of the disease. The information serves as a resource to help in better management of cancer patients and understanding cancer biology when planning medical research projects. The book is intended as a reference for a diverse audience: biomedical science students, medical students, academics, researchers, clinicians and multidisciplinary teams involved in cancer management and research.


Biomedical science students, medical students, academics, researchers, clinicians and multidisciplinary teams involved in cancer management and research.


CANCER is the leading cause of the world’s death toll and has the greatest adverse economic impact from premature death and disability, ultimately causes of death worldwide. Its economic burden is 1.5 percent of the world’s gross domestic product (GDP), around $900 billion excluding direct medical costs, which is 19 percent higher than heart disease. Thus, alleviating cancer will save millions of lives and billions of dollars.

The burden of cancer and economic impacts can be improved, if the disease is diagnosed with precancerous lesions or even early-stage of cancer. Also, the quality of life of patients could be improved by providing personalized treatment and counselling based on the prognosis of the disease. However, robust and effective markers for screening, diagnosis, prognosis and prediction are yet to be established.

The book ‘Current Cancer Biomarkers’ provides a comprehensive review, and details the clinical implications of currently useful and potential biomarkers for screening, diagnosis and management of patients with cancer. This book could help clinicians, medical students and researchers, at least to some extent, to collect scientific and clinical information on cancer biomarkers.

Professor of Physics & Dean
Faculty of Science, University of Rajshahi